CA2458821C - Use of non-toxic crosslinking agents to inhibit mechanical degradation of collagenous tissues - Google Patents

Use of non-toxic crosslinking agents to inhibit mechanical degradation of collagenous tissues Download PDF

Info

Publication number
CA2458821C
CA2458821C CA 2458821 CA2458821A CA2458821C CA 2458821 C CA2458821 C CA 2458821C CA 2458821 CA2458821 CA 2458821 CA 2458821 A CA2458821 A CA 2458821A CA 2458821 C CA2458821 C CA 2458821C
Authority
CA
Canada
Prior art keywords
tissue
collagenous tissue
crosslinking reagent
crosslinking
collagenous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA 2458821
Other languages
English (en)
French (fr)
Other versions
CA2458821A1 (en
Inventor
Thomas P. Hedman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spinal Simplicity LLC
Original Assignee
ORTHOPEUTICS LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23228386&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2458821(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ORTHOPEUTICS LP filed Critical ORTHOPEUTICS LP
Publication of CA2458821A1 publication Critical patent/CA2458821A1/en
Application granted granted Critical
Publication of CA2458821C publication Critical patent/CA2458821C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
CA 2458821 2001-08-31 2002-08-29 Use of non-toxic crosslinking agents to inhibit mechanical degradation of collagenous tissues Expired - Lifetime CA2458821C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31628701P 2001-08-31 2001-08-31
US60/316,287 2001-08-31
PCT/US2002/027677 WO2003020031A1 (en) 2001-08-31 2002-08-29 Use of non-toxic crosslinking reagents to improve fatigue resistance and reduce mechanical degradation of intervertebral disc and other collagenous tissues

Publications (2)

Publication Number Publication Date
CA2458821A1 CA2458821A1 (en) 2003-03-13
CA2458821C true CA2458821C (en) 2012-01-10

Family

ID=23228386

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2458821 Expired - Lifetime CA2458821C (en) 2001-08-31 2002-08-29 Use of non-toxic crosslinking agents to inhibit mechanical degradation of collagenous tissues

Country Status (7)

Country Link
US (2) US9084772B2 (https=)
EP (1) EP1432312B1 (https=)
JP (1) JP2005501874A (https=)
CN (1) CN1578624A (https=)
AU (1) AU2002335683B2 (https=)
CA (1) CA2458821C (https=)
WO (1) WO2003020031A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186199B2 (en) 2022-11-15 2025-01-07 Spinal Simplicity, Llc Shield for spinal defect

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436143B1 (en) * 1999-02-22 2002-08-20 Anthony C. Ross Method and apparatus for treating intervertebral disks
US6723335B1 (en) 2000-04-07 2004-04-20 Jeffrey William Moehlenbruck Methods and compositions for treating intervertebral disc degeneration
WO2012006095A1 (en) 2010-06-28 2012-01-12 Hedman Thomas P Tissue crosslinking for treatment of snoring and obstructive sleep apnea
US7435722B2 (en) * 2001-08-31 2008-10-14 University Of Southern California Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability
US8022101B2 (en) * 2001-08-31 2011-09-20 Orthopeutics, L.P. Method of treating a knee meniscus with a cross-linking reagent to increase resistance to tearing or rupturing
US20070202143A1 (en) * 2001-08-31 2007-08-30 Hedman Thomas P Direct application of non-toxic crosslinking reagents to restabilize surgically destabilized intervertebral joints
US8119599B2 (en) * 2001-08-31 2012-02-21 Orthopeutics, L.P. Direct application of non-toxic crosslinking reagents to resist progressive spinal degeneration and deformity
CA2536415C (en) * 2001-08-31 2013-07-23 University Of Southern California Crosslinking reagent for treating intervertebral disc disorders
US20050209699A1 (en) * 2002-03-19 2005-09-22 Slivka Michael A Method for nonsurgical treatment of the nucleus pulposus of the intervertebral disc using genipin or proanthrocyanidin, and kit therefor
US6812211B2 (en) 2002-03-19 2004-11-02 Michael Andrew Slivka Method for nonsurgical treatment of the intervertebral disc and kit therefor
JP2009525327A (ja) * 2006-02-02 2009-07-09 ヘドマン，トム 進行性の脊髄の奇形に抵抗する非毒性架橋試薬の直接的なアプリケーション
US20090123581A1 (en) * 2006-06-09 2009-05-14 The Board Of Trustees Of The University Of Illinois Collagen cross-linking agents on dental restorative treatment and preventive dentistry
US20080065218A1 (en) * 2006-09-13 2008-03-13 O'neil Michael J Annulus fibrosus repair devices and techniques
US20080172126A1 (en) * 2006-10-03 2008-07-17 Reynolds Martin A Nucleus pulposus injection devices and methods
KR20230146124A (ko) 2006-10-06 2023-10-18 셀룰래리티 인코포레이티드 천연(텔로펩티드) 태반 콜라겐 조성물
US10278947B2 (en) 2007-02-28 2019-05-07 Orthopeutics, L.P. Crosslinker enhanced repair of connective tissues
US8557319B2 (en) 2008-03-28 2013-10-15 Wild Flavors, Inc. Stable natural color process, products and use thereof
US20130085569A1 (en) 2010-05-27 2013-04-04 Orthopeutics, L.P. Crosslinker enhanced repair of knee meniscus
US9339478B2 (en) * 2011-02-04 2016-05-17 Reckitt Benckiser Llc Pharmaceutical formulation
EA028521B1 (ru) 2011-11-07 2017-11-30 Уайлд Флэйворс, Инк. Богатый генипином материал и его применение
EP3838280A1 (en) 2012-12-07 2021-06-23 Celularity Inc. Treating oral lesions using placental extracellular matrix
WO2014165023A1 (en) 2013-03-12 2014-10-09 Carnegie Mellon University Coated vaso-occclusive device for treatment of aneurysms
NO2975611T3 (https=) 2013-03-15 2018-06-09
JP2016526387A (ja) 2013-06-24 2016-09-05 アントフロゲネシス コーポレーション 細胞培養のための細胞外マトリクス組成物ビーズ
ES2667821B1 (es) * 2016-10-14 2019-02-22 Univ Granada Membranas bioartificiales de rigidez y viscoelasticidad controlada para su utilizacion en ingenieria tisular
JP6994147B2 (ja) * 2016-10-31 2022-02-15 地方独立行政法人東京都立産業技術研究センター 高分子多糖類又はタンパク質架橋用架橋剤及びその製造方法、架橋高分子多糖類又は架橋タンパク質形成用ゾル及びその製造方法
CN120733129B (zh) * 2025-08-28 2025-11-14 浙江珂瑞康生物医疗科技有限公司 一种胶原双相体系交联材料及其制备方法和植入支架

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270446A (en) * 1989-04-04 1993-12-14 Suntory Limited Decolorized crosslinked products and method for decolorization of crosslinked products
JPH02263833A (ja) 1989-04-04 1990-10-26 Suntory Ltd イリドイド化合物により架橋された形成物の脱色方法及び脱色された架橋形成物
KR920702383A (ko) * 1989-08-28 1992-09-03 원본미기재 치료제의 방출을 조절하는데 유용한 생부식성 중합체
KR100218052B1 (ko) * 1992-07-15 1999-09-01 이병언 B형 간염 바이러스의 복제를 억제하는 약학적 제제
FI955691L (fi) * 1994-11-28 1996-05-29 Suntory Ltd Lipoproteiini(a):ta alentava aine, kolesterolia alentava aine ja näitä aineita sisältävät lääkkeet
WO1998019718A1 (en) * 1996-11-05 1998-05-14 Challenge Bioproducts Co., Ltd. Chemical modification of biomedical materials with genipin
AU7781498A (en) * 1997-06-04 1998-12-21 Biocompatibles Limited Zwitterionic compounds and their use to cross-link collagenous materials
US6375672B1 (en) * 1999-03-22 2002-04-23 Board Of Trustees Of Michigan State University Method for controlling the chemical and heat induced responses of collagenous materials
AU6918700A (en) * 1999-08-20 2001-03-19 Howard Murad Pharmaceutical compositions and methods for reducing the appearance of cellulite
US6812211B2 (en) * 2002-03-19 2004-11-02 Michael Andrew Slivka Method for nonsurgical treatment of the intervertebral disc and kit therefor
JP2004214443A (ja) 2003-01-06 2004-07-29 Nec Corp 折り畳み式電子装置

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186199B2 (en) 2022-11-15 2025-01-07 Spinal Simplicity, Llc Shield for spinal defect

Also Published As

Publication number Publication date
EP1432312A1 (en) 2004-06-30
US20110082199A1 (en) 2011-04-07
AU2002335683B2 (en) 2008-11-20
EP1432312B1 (en) 2019-01-09
US20030049301A1 (en) 2003-03-13
EP1432312A4 (en) 2004-12-08
JP2005501874A (ja) 2005-01-20
CA2458821A1 (en) 2003-03-13
WO2003020031A1 (en) 2003-03-13
US9084772B2 (en) 2015-07-21
US9101602B2 (en) 2015-08-11
CN1578624A (zh) 2005-02-09

Similar Documents

Publication Publication Date Title
CA2458821C (en) Use of non-toxic crosslinking agents to inhibit mechanical degradation of collagenous tissues
AU2002335683A1 (en) Use of non-toxic crosslinking reagents to improve fatigue resistance and reduce mechanical degradation of intervertebral disc and other collagenous tissues
US8211938B2 (en) Direct application of non-toxic crosslinking reagents to resist progressive spinal degeneration and deformity
US8450276B2 (en) Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability
US8119599B2 (en) Direct application of non-toxic crosslinking reagents to resist progressive spinal degeneration and deformity
US7435722B2 (en) Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability
WO2008118278A1 (en) Direct application of non-toxic crosslinking reagents to restabilize surgically destabilized intervertebral joints
US8153600B2 (en) Direct application of non-toxic crosslinking reagents to resist progressive spinal deformity
US20080260712A1 (en) Non-toxic crosslinking reagents to resist curve progression in scoliosis and increase disc permeability
CA2639976A1 (en) Direct application of non-toxic crosslinking reagents to resist progressive spinal deformity
HK1074147A (en) Use of non-toxic crosslinking reagents to improve fatigue resistance and reduce mechanical degradation of intervertebral disc and other collagenous tissues
KR101238647B1 (ko) 추간판 장애의 치료를 위한 교차결합제

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20220829